[go: up one dir, main page]
Skip to main content
SpringerLink
Log in

Radiolabeled FAPI

  • Chapter
  • First Online:
Radiopharmaceuticals

  • 102 Accesses

Abstract

This chapter describes the interesting role of PET with radiolabeled fibroblast activation protein inhibitors (FAPIs), underlining the potential clinical indications. Furthermore, the emerging role of FAPI PET is highlighted with interesting clinical cases. In addition synthesis, pharmacokinetics and physiological distribution of FAPIs, and PET acquisition protocols are described as well.

The authors declare they have obtained permission for any previously published material used in their chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lindner T, Altmann A, Giesel F, et. 18F-labeled tracers targeting fibroblast activation protein. EJNMMI Radiopharm Chem. 2021;6:26.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Hicks RJ, Roselt PJ, Kallur KG, et al. FAPI PET/CT: will it end the hegemony of 18F-FDG in oncology? J Nucl Med. 2021;62:296–302.

    Article  CAS  PubMed  Google Scholar 

  5. Lindner T, Loktev A, Altmann A, et al. Development of Quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.

    Article  CAS  PubMed  Google Scholar 

  6. Toms J, Kogler J, Maschauer S, et al. Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an 18F-labeled FAP inhibitor. J Nucl Med. 2020;61:1806–13.

    Article  CAS  PubMed  Google Scholar 

  7. Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–63.

    Article  CAS  PubMed  Google Scholar 

  8. Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev. 2003;22:259–69.

    Article  PubMed  Google Scholar 

  9. Bughda R, Dimou P, D’Souza RR, Klampatsa A. Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma. Immunotargets Ther. 2021;10:313–23.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Giesel FL, Kratochwil C, Lindner T, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mona CE, Benz MR, Hikmat F, et al. Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study. J Nucl Med. 2022;63:1021–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Giesel FL, Adeberg S, Syed M, et al. FAPI-74 PET/CT using either 18F-AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62:201–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Dabir M, Novruzov E, Mattes-György K, et al. Distinguishing benign and malignant findings on [68 Ga]-FAPI PET/CT based on quantitative SUV measurements. Mol Imaging Biol. 2022;25:324. https://doi.org/10.1007/s11307-022-01759-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Giesel FL, Kratochwil C, Schlittenhardt J, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021;48:4377–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gilardi L, Airò Farulla LS, Demirci E, et al. Imaging cancer-associated fibroblasts (CAFs) with FAPi PET. Biomedicines. 2022;10:523.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dendl K, Koerber SA, Finck R, et al. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021;48:4089–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kessler L, Ferdinandus J, Hirmas N, et al. Pitfalls and common findings in 68Ga-FAPI PET: a pictorial analysis. J Nucl Med. 2022;63:890–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cimini A, Ricci M, Gigliotti PE, et al. Medical imaging in the diagnosis of schistosomiasis: a review. Pathogens. 2021;10:1058.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30:1002–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–9.

    Article  CAS  PubMed  Google Scholar 

  22. Sollini M, Kirienko M, Gelardi F, et al. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:4396–414.

    Article  PubMed  Google Scholar 

  23. Guglielmo P, Guerra L. Radiolabeled fibroblast activation protein inhibitor (FAPI) PET in oncology: has the time come for 18F-fluorodeoxyglucose to think to a well-deserved retirement? Clin Translat Imaging. 2020;9:1–2.

    Article  Google Scholar 

  24. Peng D, He J, Liu H, et al. FAPI PET/CT research progress in digestive system tumours. Dig Liver Dis. 2022;54:164–9.

    Article  CAS  PubMed  Google Scholar 

  25. Zhao L, Chen J, Pang Y, et al. Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review. Theranostics. 2022;12:1557–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Dendl K, Finck R, Giesel FL, et al. FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies. Eur J Nucl Med Mol Imaging. 2022;49:721–31.

    Article  CAS  PubMed  Google Scholar 

  27. Zhao L, Pang Y, Zheng H, et al. Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:3606–17.

    Article  CAS  PubMed  Google Scholar 

  28. Zheng J, Liu F, Lin K, et al. [68Ga]Ga-FAPI PET/CT improves the T staging of patients with newly diagnosed nasopharyngeal carcinoma: a comparison with [18F]F-FDG. Mol Imaging Biol. 2022;24:973. https://doi.org/10.1007/s11307-022-01748-8.

    Article  CAS  PubMed  Google Scholar 

  29. Qin C, Liu F, Huang J, et al. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48:3228–37.

    Article  CAS  PubMed  Google Scholar 

  30. Shang Q, Zhao L, Pang Y, et al. 68Ga-FAPI PET/CT distinguishes the reactive lymph nodes from tumor metastatic lymph nodes in a patient with nasopharyngeal carcinoma. Clin Nucl Med. 2022;47:367–8.

    Article  PubMed  Google Scholar 

  31. Linz C, Brands RC, Kertels O, et al. Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity—initial experience and comparison to [18F]FDG PET/CT and MR. Eur J Nucl Med Mol Imaging. 2021;48:3951–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chen S, Chen Z, Zou G, et al. Accurate preoperative staging with [68Ga]Ga-FAPI PET/CT for patients with oral squamous cell carcinoma: a comparison to 2-[18F]FDG PET/CT. Eur Radiol. 2022;32:6070–9.

    Article  CAS  PubMed  Google Scholar 

  33. Serfling S, Zhi Y, Schirbel A, et al. Improved cancer detection in Waldeyer's tonsillar ring by 68Ga-FAPI PET/CT imaging. Eur J Nucl Med Mol Imaging. 2021;48:1178–87.

    Article  CAS  PubMed  Google Scholar 

  34. Fu H, Fu J, Huang J, et al. 68Ga-FAPI PET/CT in thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy. Clin Nucl Med. 2021;46:427–30.

    Article  PubMed  Google Scholar 

  35. Fu H, Wu J, Huang J, et al. 68Ga fibroblast activation protein inhibitor PET/CT in the detection of metastatic thyroid cancer: comparison with 18F-FDG PET/CT. Radiology. 2022;304:397–405.

    Article  PubMed  Google Scholar 

  36. Chen Y, Zheng S, Zhang J, et al. 68Ga-DOTA-FAPI-04 PET/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients. Ann Nucl Med. 2022;36:610–22.

    Article  CAS  PubMed  Google Scholar 

  37. Kuyumcu S, Işık EG, Sanli Y. Liver metastases from medullary thyroid carcinoma detected on 68Ga-FAPI-04 PET/CT. Endocrine. 2021;74:727–8.

    Article  CAS  PubMed  Google Scholar 

  38. Gu B, Xu X, Zhang J, et al. The added value of 68Ga-FAPI PET/CT in patients with head and neck cancer of unknown primary with 18F-FDG-negative findings. J Nucl Med. 2022;63:875–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Chen H, Zhao L, Ruan D, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48:73–86.

    Article  PubMed  Google Scholar 

  40. Pang Y, Zhao L, Luo Z, et al. Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021;298:393–402.

    Article  PubMed  Google Scholar 

  41. Jiang D, Chen X, You Z, et al. Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging. 2022;49:732–42.

    Article  CAS  PubMed  Google Scholar 

  42. Zhang S, Wang W, Xu T, et al. Comparison of diagnostic efficacy of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT for staging and restaging of gastric cancer. Front Oncol. 2022;12:925100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Qin C, Shao F, Gai Y, et al. 68Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with 18F-FDG PET/CT. J Nucl Med. 2022;63:81–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Fu L, Huang S, Wu H, et al. Superiority of [68Ga] Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. Eur Radiol. 2022;32:6281–90.

    Article  CAS  PubMed  Google Scholar 

  45. Zhao L, Chen S, Chen S, et al. 68Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiother Oncol. 2021;158:55–61.

    Article  CAS  PubMed  Google Scholar 

  46. Liu H, Hu Z, Yang X, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG uptake in esophageal cancer. Front Oncol. 2022;12:875081.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Zhao L, Chen S, Lin L, et al. [68Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer. Eur J Nucl Med Mol Imaging. 2020;47:3188–9.

    Article  PubMed  Google Scholar 

  48. Pang Y, Zhao L, Shang Q, et al. Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:1322–37.

    Article  CAS  PubMed  Google Scholar 

  49. Röhrich M, Naumann P, Giesel FL, et al. Impact of 68Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62:779–86.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Wang H, Zhu W, Ren S, et al. 68Ga-FAPI-04 versus 18F-FDG PET/CT in the detection of hepatocellular carcinoma. Front Oncol. 2021;11:693640.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Guo W, Pang Y, Lao L, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48:1604–17.

    Article  CAS  PubMed  Google Scholar 

  52. Sahin E, Elboga U, Celen YZ, et al. Comparison of 68Ga-DOTA-FAPI and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. Eur J Radiol. 2021;142:109867.

    Article  PubMed  Google Scholar 

  53. Siripongsatian D, Promteangtrong C, Kunawudhi, et al. Intense 68Ga-FAPI-46 activity in lesions of recurrent ovarian clear cell carcinoma that were negative on FDG PET/CT study. Clin Nucl Med. 2022;47:e210–2.

    Article  PubMed  Google Scholar 

  54. Kömek H, Can C, Güzel Y, et al. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann Nucl Med. 2021;35:744–52.

    Article  PubMed  Google Scholar 

  55. Ding F, Huang C, Liang C, et al. 68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2021;49:290–300.

    Article  CAS  PubMed  Google Scholar 

  56. Elboga U, Sahin E, Kus T, et al. Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer. Ann Nucl Med. 2021;35:1321–31.

    Article  CAS  PubMed  Google Scholar 

  57. Backhaus P, Burg MC, Roll W, et al. Simultaneous FAPI PET/MRI targeting the fibroblast-activation protein for breast cancer. Radiology. 2022;302:39–47.

    Article  PubMed  Google Scholar 

  58. Wang L, Tang G, Hu K, et al. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the evaluation of advanced lung cancer. Radiology. 2022;303:191–9.

    Article  PubMed  Google Scholar 

  59. Wu J, Deng H, Zhong H, et al. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the evaluation of patients with newly diagnosed non-small cell lung cancer. Front Oncol. 2022;12:924223.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Fu W, Liu L, Liu H, et al. Increased FAPI uptake in brain metastasis from lung cancer on 68Ga-FAPI PET/CT. Clin Nucl Med. 2021;46:e1–2.

    Article  PubMed  Google Scholar 

  61. Giesel FL, Heussel CS, Lindner T, et al. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging. 2019;46:1754–5.

    Article  PubMed  Google Scholar 

  62. Can C, Kepenek F, Kömek H, et al. Comparison of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer. Nucl Med Commun. 2022;43:1084–91.

    Article  CAS  PubMed  Google Scholar 

  63. Wei Y, Cheng K, Fu Z, et al. [18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer. Eur J Nucl Med Mol Imaging. 2022;49:1671–81.

    Article  CAS  PubMed  Google Scholar 

  64. Kessler L, Ferdinandus J, Hirmas N, et al. 68Ga-FAPI as a diagnostic tool in sarcoma: data from the 68Ga-FAPI PET prospective observational trial. J Nucl Med. 2022;63:89–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Gu B, Liu X, Wang S, et al. Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging. 2022;49:2889–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Guzel Y, Can C, Söğütçü N, et al. 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT findings of abdominal Leiomyosarcoma. Clin Nucl Med. 2021;46:e594–7.

    Article  PubMed  Google Scholar 

  67. Dong A, Zhang Z, Yang Q, et al. 68 Ga-FAPI-04 versus 18 F-FDG PET/CT in a case with intimal sarcoma of the pulmonary artery. Clin Nucl Med. 2022;47:748–50.

    Article  PubMed  Google Scholar 

  68. Tatar G, Beyhan E, Erol Fenercioğlu Ö, et al. Comparison of 18F-FDG and 68Ga-FAPI PET/CT in gastric Kaposi sarcoma. Clin Nucl Med. 2022;47:e596–9.

    Article  PubMed  Google Scholar 

  69. Zhang L, Liu Z, Jiang S, et al. 68 Ga-FAPI versus 18 F-FDG PET/CT in recurrent undifferentiated pleomorphic sarcoma of colon mesentery. Clin Nucl Med. 2022;47:e651–3.

    Article  PubMed  Google Scholar 

  70. Wu J, Zhang S, Rao Z, et al. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in dermatofibrosarcoma protuberans. Clin Nucl Med. 2022;47:629–31.

    Article  PubMed  Google Scholar 

  71. Xu T, Ding H, Ban H, et al. 68 Ga-DOTA-FAPI-04 PET/CT imaging in a case of cardiac Angiosarcoma. Clin Nucl Med. 2022;47:834–5.

    Article  PubMed  Google Scholar 

  72. Yang X, Ou L, Xu D, et al. Increased 68Ga-FAPI activity in chondrosarcoma of nasal cavity. Clin Nucl Med. 2022;47:425–6.

    Article  PubMed  Google Scholar 

  73. Qiu S, Zou S, Cheng S, et al. Positive FAPI PET/CT in a bilateral mammary Angiosarcoma patient with less impressive FDG PET/CT images. Clin Nucl Med. 2022;47:648–50.

    Article  PubMed  Google Scholar 

  74. Jin X, Wei M, Wang S, et al. Detecting fibroblast activation proteins in lymphoma using 68Ga-FAPI PET/CT. J Nucl Med. 2022;63:212–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Lan L, Liu H, Wang Y, et al. The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG. Eur J Nucl Med Mol Imaging. 2022;49:963–79.

    Article  CAS  PubMed  Google Scholar 

  76. Zhang Y, Cai J, Lin Z, et al. Primary central nervous system lymphoma revealed by 68Ga-FAPI and 18F-FDG PET/CT. Clin Nucl Med. 2021;46:e421–3.

    Article  PubMed  Google Scholar 

  77. Kou Y, Yao Z, Cheng Z. Hepatic lesion of mucosa-associated lymphoid tissue lymphoma revealed by Al18F-NOTA-FAPI-04 PET/CT. Clin Nucl Med. 2022;47:e49–51.

    Article  PubMed  Google Scholar 

  78. Pang Y, Zhao L, Shang Q, et al. 18F-FDG versus 68Ga-FAPI PET/CT in visualizing primary hepatic Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. Clin Nucl Med. 2022;47:375–7.

    Article  PubMed  Google Scholar 

  79. Fortunati E, Argalia G, Zanoni L, et al. New PET radiotracers for the imaging of neuroendocrine neoplasms. Curr Treat Options in Oncol. 2022;23:703–20.

    Article  Google Scholar 

  80. Kreppel B, Gonzalez-Carmona MA, Feldmann G, et al. Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours. Nuklearmedizin. 2021;60:344–54.

    Article  PubMed  Google Scholar 

  81. Hotta M, Rieger AC, Javarfand MG, et al. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol. 2022;96:20220463.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Dendl K, Koerber SA, Kratochwil C, et al. FAP and FAPI-PET/CT in malignant and non-malignant diseases: a perfect symbiosis? Cancers (Basel). 2021;13:4946.

    Article  CAS  PubMed  Google Scholar 

  83. Luo Y, Pan Q, Xu H, et al. Active uptake of 68Ga-FAPI in Crohn's disease but not in ulcerative colitis. Eur J Nucl Med Mol Imaging. 2021;48:1682–3.

    Article  PubMed  Google Scholar 

  84. Treglia G, Muoio B, Roustaei H, et al. Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [18F]F-FDG in oncology: a systematic review. Int J Mol Sci. 2021;22:11192.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Wu C, Zhang X, Zeng Y, et al. [18F]FAPI-42 PET/CT versus [18F]FDG PET/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors. Eur J Nucl Med Mol Imaging. 2022;50:194. https://doi.org/10.1007/s00259-022-05955-x. Online ahead of print.

    Article  CAS  PubMed  Google Scholar 

  86. Hu K, Wang L, Wu H, et al. [18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2022;49:2833–43.

    Article  CAS  PubMed  Google Scholar 

  87. Ballal S, Yadav MP, Moon ES, et al. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2021;48:1915–31.

    Article  CAS  PubMed  Google Scholar 

  88. Mehranian A, Arabi H, Zaidi H. Vision 20/20: magnetic resonance imaging-guided attenuation correction in PET/MRI: challenges, solutions, and opportunities. Med Phys. 2016;43:1130–55.

    Article  PubMed  Google Scholar 

  89. Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3:8.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, St. Salvatore Hospital, L’Aquila, Italy

    Andrea Cimini & Fabio Cusella

  2. Nuclear Medicine Unit, Cardarelli Hospital, Campobasso, Italy

    Maria Ricci

  3. UOC Nuclear Medicine, P.O. Pescara Santo Spirito, Pescara, Italy

    Laura Travascio

  4. Razavi Cancer Research Center, Imam Reza International University, Mashhad, Iran

    Habibollah Dadgar & Nasim Norouzbeigi

  5. Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, Switzerland

    Hossein Arabi & Habib Zaidi

  6. Geneva University, Geneva, Switzerland

    Habib Zaidi

  7. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

    Habib Zaidi

  8. Department of Nuclear Medicine, University of Southern Denmark, Odense, Denmark

    Habib Zaidi

  9. Dubai Nuclear Medicine & Molecular Imaging Center, Dubai Academic Health Corporation, Dubai, UAE

    Batool Albalooshi

Authors
  1. Andrea Cimini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Ricci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura Travascio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Habibollah Dadgar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hossein Arabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fabio Cusella
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nasim Norouzbeigi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Habib Zaidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Batool Albalooshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine and Theranostics, Mariano Santo Hospital, Cosenza, Italy

    Ferdinando Calabria

  2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

    Orazio Schillaci

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cimini, A. et al. (2024). Radiolabeled FAPI. In: Calabria, F., Schillaci, O. (eds) Radiopharmaceuticals. Springer, Cham. https://doi.org/10.1007/978-3-031-54196-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-54196-4_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-54195-7

  • Online ISBN: 978-3-031-54196-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation